SCHEMBL2933640

SCHEMBL2933640

O=C(O)c1ccc(Nc2cncc(Cl)n2)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 2/20 0.48
BCL6 P41182 1/20 0.45
BCOR Q6W2J9 1/20 0.45
AURKA O14965 3/20 0.45
TSHR P16473 1/20 0.44
LRRK2 Q5S007 1/20 0.42
CSNK2A2 P19784 2/20 0.41
CSNK2A1 P68400 2/20 0.41
CSNK2B P67870 1/20 0.41
PDK1 Q15118 1/20 0.41
PDK2 Q15119 1/20 0.41
PDK3 Q15120 1/20 0.41
PDK4 Q16654 1/20 0.41
PIM3 Q86V86 3/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
PYGL P06737 2/20 0.40
DHODH Q02127 1/20 0.40
AKR1C3 P42330 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2929139 0.86 AKR1C3 (0.46) CDK2LRRK2PIM3ALDH1A1MAPT
SCHEMBL2932362 0.84 LRRK2 (0.57) CDK2AURKALRRK2CSNK2A1PIM3
SCHEMBL2935985 0.82 PIM3 (0.58) CDK2AURKALRRK2CSNK2A1PIM3
SCHEMBL2927502 0.81 PIM3 (0.51) BCL6BCORAURKAPIM3
SCHEMBL2932811 0.80 CDK2 (0.66) CDK2AURKAPIM3MAPTKMT2A
SCHEMBL6657536 0.77 HCAR3 (0.55) CDK2
SCHEMBL2935136 0.76 BCL6 (0.43) CDK2BCL6BCORAURKACSNK2A2
SCHEMBL2928690 0.74 AURKA (0.47) CDK2BCL6BCORAURKATSHR
SCHEMBL2936464 0.74 LRRK2 (0.47) CDK2AURKALRRK2PIM3ALDH1A1
SCHEMBL23501659 0.73 KDM4C (0.43) CDK2ALDH1A1AKR1C3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
EP-2044051-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (publ) (SE) 2009-04-08 EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 CDK2 182/4885BCL6 4594/4885BCOR 3225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.